慢性肝病合并2型糖尿病的rs2943650位点变异及胰岛素抵抗之间的关系

窦爱华; 惠威; 刘梅; 魏琳琳; 赵娟; 马春华; 郑小勤; 熊芳; 杨雪; 张美; 徐斌

doi:10.3969/j.issn.1001-5256.2018.11.022

慢性肝病合并2型糖尿病的rs2943650位点变异及胰岛素抵抗之间的关系

DOI: 10.3969/j.issn.1001-5256.2018.11.022

首都医科大学附属北京佑安医院肝病内分泌科

基金项目:

北京卫生系统高技术人才培养项目基金(2015-3-104)；北京市教委科技计划面上项目(KM201610025021)；北京市医院管理局临床医学发展专项(XMLX201830)；

详细信息

中图分类号: R587.1;R575
计量
- 文章访问数: 2017
- HTML全文浏览量: 37
- PDF下载量: 329
- 被引次数: 31
出版历程
- 出版日期: 2018-11-20

Association between rs2943650 mutation and insulin resistance in patients with chronic liver disease and type 2 diabetes mellitus

Research funding:

摘要

摘要:
目的探讨肝病合并糖尿病患者中胰岛素抵抗的特点,并寻找导致胰岛素抵抗的可能途径。方法选取2017年9月-2018年3月北京佑安医院收治的肝病合并2型糖尿病患者67例,分析在慢性肝炎及肝硬化阶段胰岛B细胞分泌功能和胰岛素抵抗情况,并检测rs2943650位点是否变异,分析该位点变异与不同程度肝损伤的胰岛素抵抗的关系。计量资料组间比较采用t检验或Kruskal Wallis H秩和检验,计数资料组间比较采用χ2检验。结果慢性肝炎合并2型糖尿病患者胰岛B细胞的分泌功能与肝硬化合并2型糖尿病患者比较差异无统计学意义（52. 72±34. 56 vs 52. 35±36. 59,t=0. 24,P=0. 99）,胰岛素抵抗指数在二者间差异具有统计学意义（1. 33±0. 62 vs 2. 08±1. 79,t=2. 27,P=0. 02）。rs2943650位点变异组胰岛素抵抗与未变异组比较差异有统计学意义（t=2. 11,P=0. 04）; rs2943650变异和未变异在肝脏疾病的不同阶段存在明显差异（χ2=6. 73,P=0. 01）,rs2943...
- 肝疾病 /
- 糖尿病,2型 /
- 胰岛素抵抗
Abstract:
Objective To investigate the features of insulin resistance in patients with liver disease and diabetes and possible pathways leading to insulin resistance. Methods A total of 67 patients with liver disease and type 2 diabetes who were admitted to Beijing You'an Hospital from September 2017 to March 2018 were enrolled. The insulin secretory function of pancreas islet B cells and insulin resistance in the stages of chronic hepatitis and liver cirrhosis were analyzed. The presence or absence rs2943650 mutation was detected, and the association between rs2943650 mutation and insulin resistance in different degrees of liver injury was analyzed. The t-test or the rank sum test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results There was no significant difference in the secretory function of pancreas islet B cells between the patients with chronic hepatitis and type 2 diabetes and those with liver cirrhosis and type 2 diabetes ( 52. 72 ± 34. 56 vs 52. 35 ± 36. 59, t = 0. 24, P = 0. 99) , while there was a significant difference in insulin resistance index ( 1. 33 ± 0. 62 vs 2. 08 ± 1. 79, t = 2. 27, P = 0. 02) . There was a significant difference in insulin resistance between the patients with rs2943650 mutation and those without such mutation ( t = 2. 11, P = 0. 04) . There was a significant difference in the presence or absence of rs2943650 mutation between different stages of liver disease ( χ2= 6. 73, P = 0. 01) , and rs2943650 mutation was more common in patients with liver cirrhosis. Conclusion In patients with chronic liver disease and diabetes, there is no significant reduction in the function of pancreas islet B cells with the increase in the degree of liver injury, while there is a significant increase in insulin resistance. The rs2943650 mutation is significantly associated with insulin resistance and increases significantly with the aggravation of liver injury, and therefore, it may be an important pathway for insulin resistance induced by liver disease and diabetes.
- liver diseases /
- diabetes mellitus, type 2 /
- insulin resistance

HTML全文

参考文献(20)

[1] ELKRIEF L, RAUTOU PE, SARIN S, et al. Diabetes mellitus in patients with cirrhosis:Clinical implications and management[J].Liver Int, 2016, 36 (7) :936-948.

[2] SHANIK MH, XU Y, SKRHA J, et al. Insulin resistance and hyperinsulinemia:Is hyperinsulinemia the cart or the horse?[J]. Diabetes Care, 2008, 31 (Suppl 2) :s262-s268.

[3] KILPELINEN TO, ZILLIKENS MC, STANCKOVA, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile[J]. Nat Genet, 2011, 43 (8) :753-760.

[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 33 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[5] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[6] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[7] Chinese Diabetes Society, Chinese Medical Association. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition) [J]. Chin J Pract Intern Med, 2018, 38 (4) :292-344. (in Chinese) 中华医学会糖尿病学分会.中国2型糖尿病防治指南[J].中国实用内科杂志, 2018, 38 (4) :292-344.

[8] ZHANG JQ. HOMA2-IR is a good basal insulin resistance index[J]. Chin J Endocrinol Metal, 2005, 21 (4) :304-305. (in Chinese) 张家庆. HOMA2-IR是个较好的胰岛素抵抗指数[J].中华内分泌代谢杂志, 2005, 21 (4) :304-305.

[9] DOU AH, ZHENG JF, LIU H, et al. The study on incidence of primary hepatic carcinoma of liver cirrhosis patients with type 2 diabetes mellitus[J]. Beijing Med J, 2013, 35 (6) :412-415. (in Chinese) 窦爱华, 郑俊福, 刘辉, 等.肝硬化合并2型糖尿病发生原发性肝癌的风险研究[J].北京医学, 2013, 35 (6) :412-415.

[10] YOU YL, DENG MH, GONG JP. The association between type 2diabetes mellitus and hepatocellular carcinoma[J]. J Clin Hepatol, 34 (8) :1793-1796. (in Chinese) 游宇来, 邓明华, 龚建平. 2型糖尿病与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (8) :1793-1796.

[11] HICKMAN IJ, MACDONALD GA. Impact of diabetes on the severity of liver disease[J]. Am J Med, 2007, 120 (10) :829-834.

[12] YANG S, JIANG XD. Clinical effect of linagliptin combined with insulin aspart 50 in treatment of hepatogenous diabetes[J]. J Clin Hepatol, 33 (5) :928-931. (in Chinese) 杨硕, 姜晓迪.利格列汀联合门冬胰岛素50治疗肝源性糖尿病的效果观察[J].临床肝胆病杂志, 2017, 33 (5) :928-931.

[13] MATTHEWSDR, HOSKERJP, RUDENSKIAS, et al. Homeostasis model assessment:Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man[J]. Diabetologia, 1985, 28 (7) :412-419.

[14] LOOS RJ, LINDGREN CM, LI S, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity[J]. Nat Genet, 2008, 40 (6) :768-775.

[15] RUNG J, CAUCHI S, ALBRECHTSEN A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia[J]. Nat Genet, 2009, 41 (10) :1110-1115.

[16] SAMANI NJ, ERDMANN J, HALL AS, et al. Genomewide association analysis of coronary artery disease[J]. N Engl J Med, 2007, 357 (5) :443-453.

[17] YANG L, PENG ZS, CAO YA, et al. Effect of glucose control on oxidative stress in patients with refractory diabetes[J]. Clin J Med Offic, 2018, 46 (1) :100-101. (in Chinese) 杨璐, 彭朝胜, 曹悦鞍, 等.血糖控制对难治性糖尿病患者氧化应激影响研究[J].临床军医杂志, 2018, 46 (1) :100-101.

[18] ROHDE K, KLS M, HOPP L, et al. IRS1 DNA promoter methylation and expression in human adipose tissue are related to fat distribution and metabolic traits[J]. Sci Rep, 2017, 7 (1) :12369.

[19] LINDGREN CM, HEID IM, RANDALL JC, et al. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution[J]. PLo S Genet, 2009, 5 (6) :e1000508.

[20] van VLIET-OSTAPTCHOUK JV, SNIEDER H, LAGOU V.Gene-lifestyle interactions in obesity[J]. Curr Nutr Rep, 2012, 1:184-196.

施引文献

期刊类型引用(25)

1.	胡馨月，文良志，王斌，魏艳玲，崔红利，陈东风. 2410例肝窦阻塞综合征患者临床特征的系统分析. 胃肠病学和肝病学杂志. 2024(01): 9-14 . 百度学术
2.	张万钦，朱芳. 狗舌草致肝窦阻塞综合征. 药物不良反应杂志. 2024(01): 56-58 . 百度学术
3.	刘盼盼，陶运生. 乙肝肝硬化合并肝窦阻塞综合征1例. 现代医药卫生. 2024(16): 2877-2880 . 百度学术
4.	白婷婷，刘钰懿，陈东风. 肝脏血管性疾病诊断与鉴别诊断. 实用肝脏病杂志. 2023(02): 153-155 . 百度学术
5.	李立，罗轶，李丽莉，蒋湘，黄燕红. 白背三七中吡咯里西啶生物碱的含量分析及风险评价. 西北药学杂志. 2023(05): 31-36 . 百度学术
6.	贾翠宇，赵大伟，冯骥良，宋文艳，王欣欣. 肝窦阻塞综合征的临床和影像学表现. 临床放射学杂志. 2022(02): 284-288 . 百度学术
7.	石玉芝，陈芳，许剑. 土三七致大鼠肝窦阻塞综合征发病机制研究. 现代医学与健康研究电子杂志. 2022(06): 99-103 . 百度学术
8.	李宗明，韩新巍，丁鹏绪，周朋利，焦德超，雷钦宇，徐苗. 经颈静脉肝内门体分流术治疗慢性期肝小静脉闭塞症疗效观察. 郑州大学学报(医学版). 2022(03): 422-426 . 百度学术
9.	尚亚男，徐浩，郭潇，王仲恺. 土三七致肝窦阻塞综合征的临床及CT特征研究. 医学影像学杂志. 2022(08): 1317-1322 . 百度学术
10.	昝珂，周颖，李耀磊，王莹，金红宇，左甜甜，马双成. 赤小豆中吡咯里西啶生物碱氮氧化物含量测定及安全风险评估. 中国药物警戒. 2022(11): 1186-1190 . 百度学术
11.	昝珂，蒋黄卉，金红宇，马双成，赵磊，孙艳涛. 中药肝毒性吡咯里西啶生物碱的质量控制研究进展. 药物分析杂志. 2021(04): 572-578 . 百度学术
12.	昝珂，周颖，李耀磊，左甜甜，金红宇，王莹，马双成. 罗布麻叶中肝毒性成分吡咯里西啶生物碱的含量分析及其初步风险评估. 中国药事. 2021(07): 757-762 . 百度学术
13.	昝珂，周颖，李耀磊，王莹，刘丽娜，金红宇，左甜甜，马双成. UPLC-MS/MS测定一点红不同部位中6种吡咯里西啶生物碱的含量. 中国中药杂志. 2021(17): 4456-4461 . 百度学术
14.	昝珂，陈翠玲，周颖，左甜甜，金红宇，王莹，马双成. 马鞭草中6个肝毒性吡咯里西啶生物碱的含量测定及风险评估. 中国实验方剂学杂志. 2021(24): 157-162 . 百度学术
15.	李惠贞，蔡剑鸣，董景辉，刘渊，任洪伟，安维民. 肝窦阻塞综合征患者临床及影像学表现分析. 中华消化病与影像杂志(电子版). 2021(06): 263-267 . 百度学术
16.	昝珂，李耀磊，周颖，左甜甜，金红宇，王莹，马双成. UPLC-MS/MS法测定大蓟中7个吡咯里西啶生物碱的含量及初步风险评估. 药物分析杂志. 2021(10): 1690-1696 . 百度学术
17.	昝珂，周颖，李耀磊，王莹，金红宇，左甜甜，刘丽娜，马双成. 半枝莲中肝毒性成分吡咯里西啶生物碱含量分析及初步风险评估. 药物评价研究. 2021(12): 2608-2613 . 百度学术
18.	昝珂，陈翠玲，周颖，金红宇，马双成，王莹. 超高效液相色谱串联质谱法测定木贼中4种吡咯里西啶生物碱. 化学分析计量. 2021(12): 38-42 . 百度学术
19.	昝珂，周颖，李耀磊，左甜甜，金红宇，王莹，马双成. 灯盏细辛中吡咯里西啶生物碱的含量分析及其肝毒性风险评估. 中国现代中药. 2021(11): 1897-1901 . 百度学术
20.	戚汝平，董景辉，李勇武，安维民，任洪伟，刘渊. 26例肝窦阻塞综合征临床及影像分析. 肝脏. 2020(02): 162-165 . 百度学术
21.	徐楠，李江，谢琴秀. 43例吡咯生物碱相关肝窦阻塞综合征临床特征及预后分析. 安徽医学. 2020(07): 797-800 . 百度学术
22.	刘少松，周晓东. 吡咯烷生物碱诱导肝窦阻塞综合征的研究进展. 临床内科杂志. 2020(04): 256-259 . 百度学术
23.	刘贞利，范作鹏，勾钰淞，柳雅立，张晶. 不同类型肝窦阻塞综合征的临床特征、发病机制与诊治. 临床肝胆病杂志. 2019(01): 208-212 . 本站查看
24.	尹昕茹，陈东风. 隐源性肝硬化诊治的临床思维. 医学研究生学报. 2019(06): 576-579 . 百度学术
25.	亓传旺，咸建春，肖丽，李阳. 土三七致肝窦阻塞综合征5例临床分析. 中国中西医结合消化杂志. 2019(07): 548-551 . 百度学术